ALZHEIMER’S DISEASE DIAGNOSTICS AND THERAPEUTICS MARKET ANALYSIS

Alzheimer’s disease diagnostics and therapeutics Market, by Product (Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others) and Diagnostics (Brain Imaging, CSF Test for Alzheimer’s Disease)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI5181
Pages :194
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Alzheimer’s disease Diagnostics and Therapeutics Market: Key Developments

In October 2021, Salk Institute, a research institute in California, U.S., initiated a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to evaluate its safety in humans.

Moreover, In June, 2021, Biogen, a multinational biotechnology company, and Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., announced a range of programs/initiatives intended to support access for all qualified patients, including traditionally underserved populations